Next Science EPA approval timely given spread of COVID-19
Next Science Limited (ASX:NXS) has received notification from the US Environmental Protection Agency (EPA) that its Hospital Cleaner Surface Disinfectant (LMN8) has been accepted for registration with clearance for inclusion on the product labelling of a Claim for effectiveness against biofilm.
Next Science is one of only three companies that have been awarded that Claim by the EPA at this time.
Further, Next Science’s Surface Disinfectant is the only EPA approved product with a biofilm Claim that is non-toxic to humans with safety glasses the only required form of personal protection equipment (PPE).
The EPA’s acceptance of the Surface Disinfectant for registration is a significant milestone for Next Science in that it reflects more than six years work to gain the EPA’s approval for a biofilm standard to be used as a product claim.
Unlike bleach and many other disinfectants in the market, Next Science’s Surface Disinfectant is a non-toxic product which uses Next Science’s patented XbioTM technology to eliminate biofilm based (and free floating) bacteria.
Xbio’s effectiveness against many types of bacteria including Golden Staph and E. coli (a common cause of diarrhea) has been validated by extensive clinical testing, multiple FDA clearances and more than 130,000 patient treatments since 2017.
Through third party laboratory testing, Next Science has not identified any evidence of bacterial resistance to its Xbio technology.
Negotiations with potential partners for commercialisation of the Surface Disinfectant are continuing.
Commenting on this development, managing director Judith Mitchell said, “Receipt of EPA registration of our Hospital Cleaner Surface Disinfectant LMN8 now gives us the opportunity to more widely assist hospitals and communities in the fight against infection.”
Next Science receives CE mark approval for Bactisure
This important development comes only a month after Next Science was advised that it had received CE Mark approval for Bactisure Surgical Lavage.
This allows Next Science to market and sell Bactisure in the European Union.
Bactisure will be sold in Europe by Zimmer Biomet, the group’s global distribution partner.
Highlighting the significance of Bactisure approval, Mitchell said, “Receipt of CE Mark approval marks a major milestone for Next Science as we pursue our mission to heal patients and save lives worldwide by addressing the impacts of biofilms on human health.“
These developments come at an important juncture given the high transmission rates of coronavirus through coming in contact with surfaces carrying bacteria.
Latest articles on Next Science Limited
More Commentary
Coke cops a 4$BN loss, the ASX stock to watch and … what’s happening on the ASX
18-06-2021
How taking risks can unlock potential
04-06-2021
NFT an investment megatrend? EMH - One stock to watch and … a bullish ASX
04-06-2021
ASX Companies increasingly adopting this practical ESG standard
01-06-2021S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.
